High Prevalence of Side Effects After Recombinant Human Thyrotropin–Stimulated Radioiodine Treatment with 30 mCi in Patients with Multinodular Goiter and Subclinical/Clinical Hyperthyroidism
Abstract
Background: Treatment of multinodular goiters (MNGs) is highly controversial. Radioiodine (RAI) therapy is a nonsurgical alternative for the elderly who decline surgery. Recently, recombinant human thyrotropin (rhTSH) has been used to augment RAI uptake and distribution. In this study, we determined the outcome of 30 mCi RAI preceded by rhTSH (0.1 mg) in euthyroid (EU) and hyperthyroid (subclinical/clinical) patients with large MNGs.
Methods: This was a prospective cohort study. Forty-two patients (age, 43–80 years) with MNGs were treated with 30 mCi RAI after stimulation with 0.1 mg of rhTSH. Patients were divided into three groups, according to thyroid function: EU (n = 18), subclinically hyperthyroid (SC-H, n = 18), and clinically hyperthyroid (C-H, n = 6). All patients underwent a 90-day low-iodine diet before treatment, and those with clinical hyperthyroidism received methimazole 10 mg daily for 30 days. Serum TSH, free thyroxine (FT4), total triiodothyronine (TT3), and thyroglobulin were measured at baseline and at 24, 48, 72, 168 hours, and 1, 3, 6, 9, 12, 18, 24, and 36 months after therapy. Thyroid volume was assessed by computed tomography at baseline and every 6 months.
Results: Patients had high iodine urinary excretion (308 ± 108 μg I/L) at baseline. TSH levels at baseline were within the normal range (1.5 ± 0.7 μU/mL) in the EU group and suppressed (<0.3 μU/mL) in the SC-H and C-H groups. After rhTSH, serum TSH peaked at 24 hours reaching 12.4 ± 5.85 μU/mL. After RAI administration, patients in both hyperthyroid groups had a higher increase in FT4 and TT3 compared with those in the EU group (p < 0.001). Thyroglobulin levels increased equally in all three groups until day 7. Thyroid volume decreased significantly in all patients. Side effects were more common in the SC-H and C-H groups (31.4% and 60.4%, respectively) compared with EU patients (17.8%). Permanent hypothyroidism was more prevalent in the EU group (50%) compared with the SC-H (11%) and C-H (16.6%) groups.
Conclusions: Patients with MNG may have subclinical and clinical nonautoimmune iodine-induced hyperthyroidism. Despite a low-iodine diet and therapy with methimazole, hyperthyroid patients have a significantly higher increase in FT4 and TT3 levels after RAI ablation. This can lead to important side effects related mostly to the cardiac system. We strongly advise that patients with SC-H and C-H be adequately treated with methimazole and low-iodine diet aiming to normalize their hyperthyroid condition before rhTSH-stimulated treatment with RAI.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Hegedüs LBonnema SJBennedbaek FN2003. Management of simple nodular goiter: current status and future perspectiveEndocr Rev24102-132. 1. Hegedüs L, Bonnema SJ, Bennedbaek FN 2003 Management of simple nodular goiter: current status and future perspective. Endocr Rev 24:102–132.
2.
Biondi BCooper DS2008. The clinical significance of subclinical thyroid dysfunctionEndocr Rev2976-131. 2. Biondi B, Cooper DS 2008 The clinical significance of subclinical thyroid dysfunction. Endocr Rev 29:76–131.
3.
Gammage MDParle JVHolder RLRoberts LMHobbs FDWilson SSheppard MCFranklyn JA2007. Association between serum free thyroxine concentration and atrial fibrillationArch Intern Med167928-934. 3. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, Sheppard MC, Franklyn JA 2007 Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 167:928–934.
4.
Rossi ACTomimori ECamargo RMedeiros-Neto G2001. Searching for iodine deficiency disorders in school children from Brazil: the Thyromobil projectThyroid11661-663. 4. Rossi AC, Tomimori E, Camargo R, Medeiros-Neto G 2001 Searching for iodine deficiency disorders in school children from Brazil: the Thyromobil project. Thyroid 11:661–663.
5.
Duarte GCTomimori EKBoriolli RAFerreira JECatarino RMCamargo RYMedeiros-Neto G2004. Echographic evaluation of the thyroid gland and urinary iodine concentration in school children from various regions of the State of São Paulo, BrazilArq Bras Endocrinol Metabol48842-848. 5. Duarte GC, Tomimori EK, Boriolli RA, Ferreira JE, Catarino RM, Camargo RY, Medeiros-Neto G 2004 Echographic evaluation of the thyroid gland and urinary iodine concentration in school children from various regions of the State of São Paulo, Brazil. Arq Bras Endocrinol Metabol 48:842–848.
6.
Camargo RYTomimori EKNeves SCRubio IGSGalrão ALKnobel MMedeiros-Neto G2008. Thyroid and the environment: exposure to excessive nutritional iodine increases the prevalence of thyroid disorders in São Paulo, BrazilEur J Endocrinol159293-299. 6. Camargo RY, Tomimori EK, Neves SC, Rubio IGS, Galrão AL, Knobel M, Medeiros-Neto G 2008 Thyroid and the environment: exposure to excessive nutritional iodine increases the prevalence of thyroid disorders in São Paulo, Brazil. Eur J Endocrinol 159:293–299.
7.
De Benoist BMcLean EAndersson MRogers L2003. Iodine deficiency in 2007: global progress since 2003Food Nutr Bull29195-202. 7. De Benoist B, McLean E, Andersson M, Rogers L 2003 Iodine deficiency in 2007: global progress since 2003. Food Nutr Bull 29:195–202.
8.
Nygaard BHegedüs LGervil MHjalgrim HSøe-Jensen PHansen JM1993. Radioiodine treatment of multinodular non-toxic goitreBr Med J307828-832. 8. Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Søe-Jensen P, Hansen JM 1993 Radioiodine treatment of multinodular non-toxic goitre. Br Med J 307:828–832.
9.
Le Moli RWesche MFTiel-Van Buul MMWiersinga WM1999. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitreClin Endocrinol (Oxf)50783-789. 9. Le Moli R, Wesche MF, Tiel-Van Buul MM, Wiersinga WM 1999 Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre. Clin Endocrinol (Oxf) 50:783–789.
10.
Wesche MFTiel-Van Buul MMLips PSmits NJWiersinga WM2001. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiterJ Clin Endocrinol Metab86998-1005. 10. Wesche MF, Tiel-Van Buul MM, Lips P, Smits NJ, Wiersinga WM 2001 A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 86:998–1005.
11.
Huysmans DAHermus ArCorstens FHBarentsz JOKloppenborg PW1994. Large, compressive goitres treated with radioiodineAnn Intern Med121757-762. 11. Huysmans DA, Hermus Ar, Corstens FH, Barentsz JO, Kloppenborg PW 1994 Large, compressive goitres treated with radioiodine. Ann Intern Med 121:757–762.
12.
Bonnema SJBertelsen HMortensen JAndersen PBKnudsen DUBastholt LHegedüs L1999. The feasibility of high dose iodine 131I treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary functionJ Clin Endocrinol Metab843636-3641. 12. Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L, Hegedüs L 1999 The feasibility of high dose iodine 131I treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 84:3636–3641.
13.
Niewlaat WAHuysmans DAvan Den Bosch HCSweep CGRoss HACorstens FHHermus AR2003. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiterJ Clin Endocrinol Metab883121-3129. 13. Niewlaat WA, Huysmans DA, van Den Bosch HC, Sweep CG, Ross HA, Corstens FH, Hermus AR 2003 Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 88:3121–3129.
14.
Nielsen VEBonnema SJBoel-Jørgensen HGrupe PHegedüs L2006. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131I therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trialArch Intern Med1661476-1482. 14. Nielsen VE, Bonnema SJ, Boel-Jørgensen H, Grupe P, Hegedüs L 2006 Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131I therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 166:1476–1482.
15.
Huysmans DANieuwlaat WErdtsieck JSchellekens APBus JWBravenboer BHermus AR2000. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodine uptake in nontoxic nodular goiterJ Clin Endocrinol Metab853592-3596. 15. Huysmans DA, Nieuwlaat W, Erdtsieck J, Schellekens AP, Bus JW, Bravenboer B, Hermus AR 2000 Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodine uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 85:3592–3596.
16.
Nielsen VEBonnema SJBoel-Jørgensen HVeje AHegedüs L2005. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trialJ Clin Endocrinol Metab9079-83. 16. Nielsen VE, Bonnema SJ, Boel-Jørgensen H, Veje A, Hegedüs L 2005 Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J Clin Endocrinol Metab 90:79–83.
17.
Silva MNRubio IGRomão RGebrin EMBuchpiguel CTomimori ECamargo RCardia MSMedeiros-Neto G2004. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitresClin Endocrinol60300-308. 17. Silva MN, Rubio IG, Romão R, Gebrin EM, Buchpiguel C, Tomimori E, Camargo R, Cardia MS, Medeiros-Neto G 2004 Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol 60:300–308.
18.
Albino CCMesa CO Jr.Olandoski MUeda CEWoellner LCGoedert CASouza AMGraf H2005. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodineJ Clin Endocrinol Metab902775-2780. 18. Albino CC, Mesa CO Jr., Olandoski M, Ueda CE, Woellner LC, Goedert CA, Souza AM, Graf H 2005 Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 90:2775–2780.
19.
Cohen OIlany JHoffman COlchovsky DDabhi SKarasik AGoshen ERotenberg GZwas ST2006. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patientsEur J Endocrinol154243-252. 19. Cohen O, Ilany J, Hoffman C, Olchovsky D, Dabhi S, Karasik A, Goshen E, Rotenberg G, Zwas ST 2006 Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol 154:243–252.
20.
Duick DSBaskin HJ2003. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goitresEndocr Pract9204-209. 20. Duick DS, Baskin HJ 2003 Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goitres. Endocr Pract 9:204–209.
21.
Paz-Filho GJMesa-Junior COOlandoski MWoellner LCGoedert CABoguszewski CLCarvalho GAGraf H2007. Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormoneBraz J Med Biol Res401661-1670. 21. Paz-Filho GJ, Mesa-Junior CO, Olandoski M, Woellner LC, Goedert CA, Boguszewski CL, Carvalho GA, Graf H 2007 Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz J Med Biol Res 40:1661–1670.
22.
Barca MFGroupi COliveira MTRomão RCárdia MSRubio IGSKnobel MMedeiros-Neto G2007. Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSHEndocrine32175-181. 22. Barca MF, Groupi C, Oliveira MT, Romão R, Cárdia MS, Rubio IGS, Knobel M, Medeiros-Neto G 2007 Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSH. Endocrine 32:175–181.
23.
Medeiros-Neto GMarui SKnobel M2008. An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiterEndocrine33109-117. 23. Medeiros-Neto G, Marui S, Knobel M 2008 An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter. Endocrine 33:109–117.
24.
Pretell EADelange FHostalek UCorigliano SBarreda LHiga AMAltschuler NBarragán DCevallos JLGonzales OJara JAMedeiros-Neto GMontes JAMuzzo SPacheco VMCordero L2004. Iodine nutrition improves in Latin AmericaThyroid14590-599. 24. Pretell EA, Delange F, Hostalek U, Corigliano S, Barreda L, Higa AM, Altschuler N, Barragán D, Cevallos JL, Gonzales O, Jara JA, Medeiros-Neto G, Montes JA, Muzzo S, Pacheco VM, Cordero L 2004 Iodine nutrition improves in Latin America. Thyroid 14:590–599.
25.
Stanbury JBErmans AEBourdoux PTodd COken ETonglet RVidor GBraverman LEMedeiros-Neto G1998. Iodine induced hyperthyroidism: occurrence and epidemiologyThyroid883-100. 25. Stanbury JB, Ermans AE, Bourdoux P, Todd C, Oken E, Tonglet R, Vidor G, Braverman LE, Medeiros-Neto G 1998 Iodine induced hyperthyroidism: occurrence and epidemiology. Thyroid 8:83–100.
26.
Fast SNielsen VEBonnema SJHegedus L2009. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapyEur J Endocrinol160517-528. 26. Fast S, Nielsen VE, Bonnema SJ, Hegedus L 2009 Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol 160:517–528.
27.
Magner J2008. Problems associated with the use of thyrogen in patients with a thyroid glandN Engl J Med3591738-1739. 27. Magner J 2008 Problems associated with the use of thyrogen in patients with a thyroid gland. N Engl J Med 359:1738–1739.
Information & Authors
Information
Published In
Copyright
Copyright 2009, Mary Ann Liebert, Inc.
History
Published online: 4 September 2009
Published in print: September 2009
Published ahead of print: 13 August 2009
Topics
Authors
Disclosure Statement
The authors declare that no competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.